This database contains 250 studies, archived under the term: "cognition"
Click here to filter this large number of results.
Assessment of cognition in mild cognitive impairment: a comparative study
Snyder, Peter J.,
Jackson, Colleen E.,
Petersen, Ronald C.,
Khachaturian, Ara S.,
Kaye, Jeffrey,
Albert, Marilyn S.,
Weintraub, Sandra
The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer’s disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective […]
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study
Sink, Kaycee M.,
Leng, Xiaoyan,
Williamson, Jeff,
Kritchevsky, Stephen B.,
Yaffe, Kristine,
Kuller, Lewis,
Yasar, Sevil,
Atkinson, Hal,
Robbins, Mike,
Psaty, Bruce,
Goff, David C.
Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; […]
Relation of hemoglobin to level of cognitive function in older persons
Shah, Raj C.,
Wilson, Robert S.,
Tang, Yuxiao,
Dong, Xinqi,
Murray, Anne,
Bennett, David A.
Background: While decreased hemoglobin concentration is common in the elderly, the relationship of the entire range of hemoglobin concentrations with cognitive function is not well understood.; Methods: Cross-sectional analyses were conducted utilizing data from community-dwelling, older persons participating in the Rush Memory and Aging Project. Proximate to first available hemoglobin measurement, 21 cognitive tests were […]
Dual-task performances can be improved in patients with dementia: a randomized controlled trial
Background: Deficits in attention-related cognitive performance measured as dual-task performance represent early markers of dementia and are associated with motor deficits and increased risk of falling. The purpose of this study was to examine the effect of a specific dual-task training in patients with mild to moderate dementia.; Methods: Sixty-one geriatric patients with confirmed dementia […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study
Sakurai, Hirofumi,
Hanyu, Haruo,
Sato, Tomohiko,
Kume, Kazumasa,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Iwamoto, Toshihiko
Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, on cognition and regional cerebral blood flow (rCBF) in elderly patients with AD and cerebrovascular disease (CVD).; Methods: A […]
Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: A randomized, placebo-controlled trial
Rosenberg, Paul B.,
Lanctôt, Krista L.,
Drye, Lea T.,
Herrmann, Nathan,
Scherer, Roberta W.,
Bachman, David L.,
Mintzer, Jacobo E.
Objective: In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer’s disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET). Method: Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer’s disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December […]
Cognitive change in donepezil treated patients with vascular or mixed dementia
Rockwood, Kenneth,
Mitnitski, Arnold,
Black, Sandra E.,
Richard, Matthew,
Defoy, Isabelle,
Vaspect study investigators
Background: vascular dementia (VaD) and mixed Alzheimer’s disease (AD/VaD) are common. How best to monitor treatment is not clear. Our objective was to compare responsiveness and construct validity of change scores, following donepezil treatment, of the standardized Mini-Mental State Examination (sMMSE) and other measures potentially usable in primary care.; Methods: A six-month, outcome measurement study. […]
Galantamine treatment in outpatients with mild Alzheimer’s disease
Objective: To assess long-term effectiveness of galantamine in community-dwelling persons with mild Alzheimer’s disease.; Methods: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers’ ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based […]